Kenya Alzheimer’s Therapeutics Market Analysis

Kenya Alzheimer’s Therapeutics Market Executive Summary

Kenya alzheimer’s therapeutics market valued at $3 Mn in 2022, projected to reach $7 Mn by 2030 with a 10.2% CAGR.

Alzheimer's disease is a neurological disorder that negatively impacts mental health, behavior, and memory. This illness usually starts slowly, worsens with time, and makes it harder for the affected person to carry out daily duties. The disorder is characterized by aberrant alterations in the brain, including the development of plaques and tangles, which ultimately result in the loss of nerve cells. As of right now, there is no proven treatment for Alzheimer's disease; but some drugs can help manage symptoms and improve quality of life. The medications, which include memantine, rivastigmine, and donepezil, alter particular neurotransmitters in the brain to treat memory and cognitive issues. Non-pharmacological methods that may aid in the overall management of a condition include creating a supportive atmosphere, taking part in social and cognitive activities, and leading a healthy lifestyle.

Kenya's population is rapidly aging, contributing to a significant demographic shift that will see the proportion of adults over 60 double by 2050. This age group's greater susceptibility to Alzheimer's disease, a disorder linked to cognitive loss and higher mortality, is concerning given the demographic trend. In Kenya, 1,827 deaths were attributable to dementia and Alzheimer's disease, accounting for 0.69% of all deaths. With an age-adjusted death rate of 18.35 per 100,000 people, Kenya is ranked 76th in the world. These figures highlight how important it is becoming to prioritize Alzheimer's disease care in Kenya, which calls for proactive approaches to prevention, more public awareness, and improved infrastructure for healthcare that is suited to the unique requirements of the country's aging population.

A significant event occurred in October 2023 when the US Food and Drug Administration (FDA) approved Lecanemab, a novel Alzheimer's medication that Eisai and Biogen co-developed. This approval represents a major advancement in the area even though the drug is not yet available in Kenya. It may pave the way for the introduction of similar drugs through licensing or local development in the future. Meanwhile, organizations like the Alzheimer's & Dementia Organisation Kenya (ADOK) are working hard to raise awareness of Alzheimer's, stress the importance of early identification, and push for improved patient access to healthcare services. This group's endeavor demonstrates a dedication to tackling the complexity of Alzheimer's disease locally and globally.

Market Dynamics

Market Growth Drivers

Rising Burden of Alzheimer's Disease: Alzheimer's disease risk is rising in Kenya due to the country's fast aging population, with 5.3 Mn people over 60 expected to exist by 2030. This shift in the population is correlated with an increased prevalence of age-related illnesses, like Alzheimer's disease. As more and more older people are developing Alzheimer's disease, there is a growing need for effective interventions. This demographic trend is a strong driver of market expansion.

Emerging Treatment Options: Late-stage clinical research on Alzheimer's therapy has yielded exciting advances that address many aspects of the illness and offer promise for improved treatments. The Tau protein aggregation-focused Etermis clinical study for EMERG-01 is an illustration of how local initiatives can improve global healthcare and eventually support the expansion of the Alzheimer's medication market.

Increased Awareness and Diagnosis: Growing public awareness of Alzheimer's disease and improved diagnostic tools are crucial for early diagnosis and timely treatment start, which increases the number of patients actively looking for effective drugs. Government initiatives to improve accessibility to diagnostic services and raise public awareness also act as catalysts for industry expansion. Together, these calculated moves create an atmosphere that supports early intervention and increases the market's need for efficacious pharmaceutical solutions, which contributes to the market's growth.

Market Restraints

Complex regulatory processes: Pharmaceutical companies face a challenging task in navigating the medication approval process, which could impede the nation's efforts to develop Alzheimer's disease medicines. Encouraging new participants with support systems and simplifying regulations may serve as stimulants and foster an environment that is conducive to innovation. Notably, one major market limitation that may deter pharmaceutical companies from actively researching and developing Alzheimer's medications is the complex and demanding regulatory environment.

High Drug Costs: The high cost of the current generation of Alzheimer's medications places a significant financial strain on both patients and their families. Due to the financial burden, getting treatment is more difficult for the general population, particularly for those with low incomes or inadequate insurance. This creates a considerable barrier to the market.

Low Public Awareness: Alzheimer's disease is stigmatized, and there is a lack of understanding about the disease's symptoms and potential treatments, which can lead to a delayed diagnosis and missed possibilities for prompt intervention. The importance of public education campaigns and awareness efforts in reducing these issues must be emphasized. Moreover, the prevalent deficiency in knowledge and comprehension leads to a significant market constraint that impedes the implementation of efficacious interventions and demands heightened efforts to educate the public and medical professionals.

Healthcare Policies and Regulatory Landscape

In Kenya, healthcare policies and regulatory bodies responsible for guaranteeing the safety, effectiveness, and accessibility of medications are in charge of monitoring and controlling treatment drugs. The primary regulatory agency responsible for the approval, registration, and oversight of pharmaceuticals in the nation is the Pharmacy and Poisons Board (PPB), which was founded under the Pharmacy and Poisons Act. Treatment medications are subjected to a stringent evaluation by the PPB before being approved for use and distribution in Kenya. Kenyan healthcare policy aims to achieve a balance between protecting the public's health and enabling prompt access to necessary drugs. The effectiveness of regulatory processes and the accessibility of treatment medications, however, can be impacted by issues including bureaucratic procedures and resource constraints.

Competitive Landscape

Key Players

• Eisai
• Biogen
• GlaxoSmithKline
• Novartis
• Pfizer
• Roche
• Johnson & Johnson,
• Eli Lilly
• AstraZeneca
• Merck & Co.